Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Argus Health
Healthtrust
Queensland Health
US Army
QuintilesIMS
Boehringer Ingelheim
Chinese Patent Office
Medtronic

Generated: January 21, 2018

DrugPatentWatch Database Preview

Ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic sources for ritonavir and what is the scope of ritonavir patent protection?

Ritonavir
is the generic ingredient in two branded drugs marketed by Abbott, Abbvie, Abbvie Inc, and West-ward Pharms Int, and is included in six NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ritonavir has seventy-eight patent family members in thirty-one countries.

There are twenty-one drug master file entries for ritonavir. Five suppliers are listed for this compound. There are five tentative approvals for this compound.
Tentative approvals for RITONAVIR
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe100MGTABLET;ORAL
➤ Subscribe➤ Subscribe100MGTABLET;ORAL
➤ Subscribe➤ Subscribe100MGTABLET;ORAL

US Patents and Regulatory Information for ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc NORVIR ritonavir POWDER;ORAL 209512-001 Jun 7, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 ➤ Subscribe ➤ Subscribe
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,405 Polymorph of a pharmaceutical ➤ Subscribe
8,333,990 Solid pharmaceutical dosage form ➤ Subscribe
6,458,818 Pharmaceutical composition ➤ Subscribe
9,255,092 Polymorph of a pharmaceutical ➤ Subscribe
8,377,952 Solid pharmaceutical dosage formulation ➤ Subscribe
6,521,651 Pharmaceutical composition ➤ Subscribe
8,193,367 Polymorph of a pharmaceutical ➤ Subscribe
7,183,416 Polymorph of a pharmaceutical ➤ Subscribe
6,894,171 Polymorph of a pharmaceutical ➤ Subscribe
8,309,613 Solid pharmaceutical dosage form ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ritonavir

Supplementary Protection Certificates for ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0674513 Switzerland ➤ Subscribe PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
C/GB01/044 United Kingdom ➤ Subscribe PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
00060 Netherlands ➤ Subscribe PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Accenture
Cipla
Fuji
Chubb
Daiichi Sankyo
Medtronic
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot